Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

TSC-101 eliminates recipient hematopoietic cells and demonstrates potential for improved relapse-free survival in patients with AML, ALL, or MDS undergoing allogeneic HCT: Updated results from the Phase 1 (ALLOHA) trial

Monzr M. Al Malki, Yi-Bin Chen, Tania Jain, Alla Keyzner, Melhem Solh, Uday Popat, Michele Donato, Luis Pineiro, Hugo Fernandez, Saar Gill, Anson Snow, Joseph Uberti, Timothy White, Yun Wang, Cuong Nguyen, Chrystal Louis, Shrikanta Chattopadhyay, Michelle Matzko, Ran Reshef

Blood (2025) 146 (Supplement 1): 2391.

https://doi.org/10.1182/blood-2025-2391

Published: 2025

Journal Articles

Trials in progress: Design of a registrational Phase 2 trial (ALLOHA) using an external control arm for TSC-101 for prevention of relapse post allogeneic HCT in patients with ALL, AML, or MDS

Blood (2025) 146 (Supplement 1): 2400.

https://doi.org/10.1182/blood-2025-2400

Published: 2025

Journal Articles

TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial

Blood (2024) 144 (Supplement 1): 924.

https://doi.org/10.1182/blood-2024-201526

Published: 2024

Journal Articles

Final Clinical Outcomes from a Phase 2 Trial of Posoleucel, an Off-the-Shelf, Multivirus-Specific T-Cell Therapy, for the Prevention of Clinically Significant Viral Infections Post-HCT

Sanjeet S Dadwal, Jo-Anne H. Young, Michael W. Schuster, Jean A. Yared, Gary Douglas Myers, Michelle Matzko, Sama Adnan, Joshua A. Hill, Rajat Bansal

Blood (2022) 140 (Supplement 1): 878–879.

https://doi.org/10.1182/blood-2022-169122

Published: 2022

Update search

NARROW

Publications

Format

Article Type

Date

Availability

TSC-101 eliminates recipient hematopoietic cells and demonstrates potential for improved relapse-free survival in patients with AML, ALL, or MDS undergoing allogeneic HCT: Updated results from the Phase 1 (ALLOHA) trial

Trials in progress: Design of a registrational Phase 2 trial (ALLOHA) using an external control arm for TSC-101 for prevention of relapse post allogeneic HCT in patients with ALL, AML, or MDS

TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial

Final Clinical Outcomes from a Phase 2 Trial of Posoleucel, an Off-the-Shelf, Multivirus-Specific T-Cell Therapy, for the Prevention of Clinically Significant Viral Infections Post-HCT

Email alerts

ASH Publications

American Society of Hematology

Update search

TSC-101 eliminates recipient hematopoietic cells and demonstrates potential for improved relapse-free survival in patients with AML, ALL, or MDS undergoing allogeneic HCT: Updated results from the Phase 1 (ALLOHA) trial

Trials in progress: Design of a registrational Phase 2 trial (ALLOHA) using an external control arm for TSC-101 for prevention of relapse post allogeneic HCT in patients with ALL, AML, or MDS

TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial

Final Clinical Outcomes from a Phase 2 Trial of Posoleucel, an Off-the-Shelf, Multivirus-Specific T-Cell Therapy, for the Prevention of Clinically Significant Viral Infections Post-HCT

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only